Nuvation Bio Inc.
New York Stock ExchangeTotal Valuation
Nuvation Bio Inc. carries a market capitalization of 1.99B, placing it among publicly traded companies globally. Its enterprise value stands at 1.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.99B |
| Enterprise Value | 1.58B |
Share Statistics
Nuvation Bio Inc. currently has 349.82M shares outstanding.
| Shares Outstanding | 349.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11.56, and the price-to-book ratio stands at 7.83.
| PE Ratio | N/A |
| PS Ratio | 11.56 |
| PB Ratio | 7.83 |
| P/TBV Ratio | 8.16 |
| P/FCF Ratio | -16.70 |
| P/OCF Ratio | -16.29 |
Enterprise Valuation
| EV / Sales | 9.29 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 27.17 |
Financial Position
Nuvation Bio Inc. maintains a current ratio of 8.37, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 99.32, indicating elevated leverage, while an interest coverage ratio of -5.08 demonstrates limited ability to service its debt obligations.
| Current Ratio | 8.37 |
| Quick Ratio | 7.98 |
| Debt / Equity | 99.32 |
| Debt / EBITDA | -1.86 |
| Interest Coverage | -5.08 |
Financial Efficiency
| Return on Equity (ROE) | -47.81 |
| Return on Assets (ROA) | -21.53 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 4.20 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.96 |
Stock Price Statistics
Nuvation Bio Inc.'s stock has gained approximately 76.85185% over the past 52 weeks. The 50-day moving average sits at 6.42, while the 200-day moving average is 5.86.
| Beta (5Y) | N/A |
| 52-Week Price Change | 76.85185% |
| 50-Day Moving Average | 6.42 |
| 200-Day Moving Average | 5.86 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nuvation Bio Inc. generated 169.90M in revenue and converted that into -149.83M in net income, yielding earnings per share of -0.42. EBITDA reached -135.48M, while operating income came in at -137.63M.
| Revenue | 169.90M |
| Gross Profit | 149.81M |
| Operating Income | -137.63M |
| Pretax Income | -149.83M |
| Net Income | -149.83M |
| EBITDA | -135.48M |
| EBIT | -137.63M |
| Earnings Per Share (EPS) | -0.42 |
Balance Sheet
Nuvation Bio Inc. holds 660.96M in cash and equivalents against 252.14M in total debt, resulting in a net debt position of -10.09M. Total book value stands at 253.86M, with working capital of 639.68M providing operational flexibility.
| Cash & Cash Equivalents | 660.96M |
| Total Debt | 252.14M |
| Net Debt | -10.09M |
| Equity (Book Value) | 253.86M |
| Book Value Per Share | 0.73 |
| Working Capital | 639.68M |
Cash Flow
Nuvation Bio Inc. produced -120.52M in operating cash flow over the past twelve months. After subtracting -403,000.00 in capital expenditures, free cash flow totaled -120.92M - equivalent to -0.35 per share.
| Operating Cash Flow | -120.52M |
| Capital Expenditures | -403,000.00 |
| Free Cash Flow | -120.92M |
| FCF Per Share | -0.35 |
Margins
Nuvation Bio Inc. operates with a gross margin of 88.18, reflecting its pricing power and cost economics. The operating margin of -81.00 and net profit margin of -88.19 provide insight into operational efficiency.
| Gross Margin | 88.18 |
| Operating Margin | -81.00 |
| Pretax Margin | -88.19 |
| Profit Margin | -88.19 |
| EBITDA Margin | -79.74 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.02 |
| FCF Yield | -5.99 |
Scores
Nuvation Bio Inc. posts an Altman Z-Score of 0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.85 |